Jupiter Neurosciences announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2a clinical trial of JOTROL, its oral resveratrol formulation, for the treatment of Parkinson’s disease. According to the company, the approval allows it to begin enrolling patients for a multi-center study assessing the drug’s safety, tolerability, and pharmacokinetics in individuals with mild to moderate Parkinson’s.
The company said that JOTROL is designed to overcome the bioavailability limitations of traditional resveratrol by improving absorption and achieving therapeutic blood levels that may benefit neurodegenerative conditions. According to Jupiter Neurosciences, the investigational therapy has already demonstrated safety and potential neuroprotective effects in earlier studies involving other central nervous system disorders, including mild cognitive impairment and traumatic brain injury.
Jupiter Neurosciences claims that the Phase 2a trial will also explore biomarker data to evaluate the compound’s effect on neuroinflammation and oxidative stress pathways, which are implicated in the progression of Parkinson’s disease. The company said it plans to begin patient recruitment in the near term and expects initial results in 2026.
According to the company, the FDA clearance represents a significant milestone in its clinical development pipeline and supports its broader strategy to advance JOTROL as a potential therapeutic option for multiple neurological and rare diseases associated with aging and metabolic dysfunction.
